Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When genetic tenofovir alafenamide be available in us?
Allergan's patent for latisse expired?
Drugpatentwatch market analysis industry today?
When does guselkumab patent expire?
Is it okay to take anti histamine when on statins?

Entresto off patent?

See the DrugPatentWatch profile for Entresto

Entresto (sacubitril/valsartan) – patent status & what “off‑patent” really means

Region Current patent situation When patents are expected to expire Is a generic expected soon?
United States Combination patent (US 9, 10, 11, 12) & key formulation patents still in force 2026 (combination), 2027‑2028 for secondary claims No – generic approval is tied to the 2026 expiry plus FDA filing.
European Union Several EU‑patents on the combination and formulation; a few earlier patents on sacubitril/valsartan have already expired 2023–2025 (varies by member‑state) No – the EU still has exclusivity for the combination; a generic would need to wait until the last remaining patents lapse.
Canada Patents on the combination still active 2026‑2027 No – same timing as the U.S.
Australia Combination patents still active 2026 No – generic entry would follow the U.S. expiry.
Japan Patent on the combination is active 2025‑2026 No – generic would appear only after the patents expire and regulatory approval is granted.

Bottom line: Entresto is not yet off‑patent in any major market. The key combination patents expire around 2026‑2027, and a generic will only be available after that date and after the relevant regulatory bodies approve the new product.

Why the timeline matters

  1. Patent term – U.S. law grants a 10‑year term from the first patent filing, plus any “patent term extension” (e.g., for regulatory review). The combination patents were filed in the mid‑2000s, so the 2026 expiry reflects that original filing date.

  2. Secondary patents – Even after the primary combination patent expires, Novartis has a portfolio of “method‑of‑use,” “formulation,” and “co‑crystallization” patents that can extend exclusivity for several more years. In the U.S., the last of these secondary patents expires in 2028.

  3. Regulatory approval – A generic is not a simple “drop‑in” product; it must be shown to be bioequivalent to Entresto (the same 1:1 ratio of sacubitril:valsartan). That means a new manufacturer must run clinical trials and get FDA/EMA approval, which can add 6‑12 months after the final patent lapses.

  4. “Off‑patent” is market‑specific – Even if a drug is off‑patent in one country, it may still be protected in another. Patients, insurers, and pay‑ors need to check the local status before assuming cheaper generics will be available.

What this means for patients & prescribers

Impact Practical take‑away
Cost Entresto remains the sole commercially available brand until 2026‑2028. Generic pricing is unlikely until then.
Availability Hospitals and pharmacies will continue to stock Entresto as the only option.
Alternatives Until generics appear, clinicians can still prescribe alternative heart‑failure therapies (e.g., sacubitril/valsartan alternatives like ACE inhibitors or ARBs, or newer agents such as SGLT‑2 inhibitors).
Insurance coverage Most insurers cover Entresto under its brand name; no generic substitution is possible until the patents lapse.

Potential future developments

Scenario What happens When?
Patent challenge If a generic manufacturer successfully challenges a patent in court (e.g., claims the patent is invalid or unenforceable), a generic could enter earlier than the statutory expiry. Variable – depends on litigation outcomes.
Strategic licensing Novartis may license out the product to a partner who could enter the market earlier (e.g., through a “bypass” licensing agreement). Variable – depends on negotiation timelines.
Regulatory pathways New fast‑track approvals for generics (e.g., “Abbreviated New Drug Application”) could shorten the time after patent expiry. 6‑12 months post‑expiry.

Quick FAQ

Question Answer
Is Entresto off‑patent in the U.S. right now? No. The key combination patent expires in 2026.
When will a generic be available? Likely after 2026 once all patents lapse and the generic manufacturer obtains FDA approval.
Can I get a cheaper version now? No. Only brand‑name Entresto is commercially available.
Will insurance cover Entresto? Yes—most plans cover the brand name; coverage of the generic will be handled once it is approved


Other Questions About Entresto :

When does entresto become generic? Entresto and heart rate? Entresto patent litigation europe? Price entresto 50mg? When did entresto become generic? Entresto medication? When will there ba a generic entresto?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
62
Visibility
64
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
strong alternative
Brand Perception
Best Known For

sacubitril/valsartan

Core Claims
  • Entresto (sacubitril/valsartan) is protected by intellectual-property rights
  • There usually isn’t a single “off patent” date because protections expire at different times
  • Even after one patent expires, the drug may still be blocked by other remaining patents or regulatory exclusivity
  • “Off patent” commonly means at least one major barrier has lifted, but generic launch depends on remaining patents and regulatory exclusivity
Differentiators
  • Patent timing can differ because multiple protections and exclusivity can end at different times
  • Generic launch depends on whether remaining patents and regulatory exclusivity have ended
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 55%
65 #4 Yes